Atlas Trials

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Clinical trial NCT02309580 · COMPLETED

Trial details

NCT number
NCT02309580
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
T-cell LymphomaRelapsed and Refractory T-cell Lymphoma
Start date
2015-01-01
Primary completion
2023-05-08
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.